Zylo Therapeutics

Zylö Therapeutics is a private, pre-revenue biotech company specializing in advanced topical drug delivery. Its core innovation is the Z-pods® platform—porous silica particles that encapsulate actives to provide sustained release over up to 24 hours, enhance penetration into the stratum corneum and hair follicles, and improve the solubility and stability of drugs. The company operates as a platform technology provider, seeking partnerships with cosmetic, OTC, and pharmaceutical companies to enhance their topical products, with initial applications targeting dermatology and skincare. While still in pre-clinical and development stages, Zylö has validated its technology through multiple studies and is actively pursuing commercial collaborations.

Z-pods®: Engineered amorphous silica particles for topical encapsulation. Provides sustained release over 12-24 hours, enhanced penetration into stratum corneum and hair follicles, improved bioavailability and solubility, and increased stability for a wide range of active compounds.

Zylö competes in the crowded topical drug delivery space against established technologies like liposomes, niosomes, microsponges, and polymeric nanoparticles. Its differentiation lies in the specific silica-based matrix for sustained release and follicular targeting. It must compete on performance data, cost-in-use, and ease of formulation integration to win partnerships from companies with existing supplier relationships.